NEW YORK (GenomeWeb) – Clinical trials matchmaker Cure Forward has signed an agreement to let its customers diagnosed with cancer select Personal Genome Diagnostics as their genomic testing service provider and access test data, the companies announced today.
In addition to its Clinical Trial Exchange to connects cancer patients with clinical trials, Cure Forward offers the Patient Activation platform, a web-based system for patients to share and access their genomic test results. Under the terms of the deal, PGDx will make its genomic testing results directly available through the Patient Activation platform in interoperable formats that can be directly applied by patients. Additional details were not disclosed.
"This collaboration with PGDx further ensures that patients using our platform will have rapid access to their data from the highest quality genomic testing services," Cure Forward Founder and Chief Strategy Officer Martin Naley said in a statement.